Ozempic-like drug significantly reduces frequency of chronic migraines in pilot study
- Italian researcher Simone Braca and colleagues conducted a 12-week pilot study testing liraglutide on 31 obese patients with chronic migraines.
- The study arose because many migraine sufferers do not find relief with existing drugs and obesity is linked to increased migraine risk.
- Participants experienced an average reduction in migraine days from around 20 to 11 per month and one patient became completely migraine-free.
- The side effects like nausea and constipation were mild and resolved during the study, while researchers propose liraglutide reduced intracranial pressure causing symptom relief.
- Though preliminary and lacking a control group, the findings suggest GLP-1 receptor agonists could become valuable add-ons for difficult migraine cases, pending further research.
6 Articles
6 Articles
Popular weight-loss drugs show promising new power against debilitating migraines
GLP-1 drugs show promise for migraine relief, reducing headache days from 20 to 11 per month in adults with obesity, with benefits appearing within two weeks regardless of weight loss.
Ozempic-like drug significantly reduces frequency of chronic migraines in pilot study
Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment options, some migraine sufferers cannot find relief in available drugs. Others experience side effects that prevent the use of certain available migraine medications.
Coverage Details
Bias Distribution
- 50% of the sources lean Left
To view factuality data please Upgrade to Premium